News articles about Alnylam Pharmaceuticals (NASDAQ:ALNY) have trended somewhat positive on Friday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.7368989327644 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $1.56 during trading on Friday, hitting $121.42. 392,170 shares of the stock traded hands, compared to its average volume of 879,798. The firm has a market capitalization of $11,940.00, a PE ratio of -22.44 and a beta of 2.68. Alnylam Pharmaceuticals has a 12 month low of $45.00 and a 12 month high of $147.63. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). The company had revenue of $37.90 million during the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The firm’s quarterly revenue was up 116.6% compared to the same quarter last year. During the same quarter last year, the company earned ($1.32) EPS. equities research analysts forecast that Alnylam Pharmaceuticals will post -6.88 EPS for the current fiscal year.
In other news, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the transaction, the senior vice president now owns 17,749 shares in the company, valued at $2,151,178.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the transaction, the vice president now owns 6,352 shares of the company’s stock, valued at approximately $835,859.68. The disclosure for this sale can be found here. Insiders sold 72,994 shares of company stock valued at $9,669,353 in the last quarter. Corporate insiders own 4.30% of the company’s stock.
WARNING: “Alnylam Pharmaceuticals (ALNY) Given Daily Media Sentiment Rating of 0.20” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://baseballnewssource.com/markets/alnylam-pharmaceuticals-alny-given-daily-media-sentiment-rating-of-0-20/1911930.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.